Key Drivers
- Margin Strength
- Cash Burn
- Rich Valuation
AIAI Summary
INSM should now be viewed as a commercial scale-up story centered on BRINSUPRI's rapid growth, but with the stock already pricing in substantial success, the key investment issue is whether management can sustain clean payer-supported demand and convert strong gross margins into real earnings and cash flow before execution risk or a launch slowdown triggers a valuation reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Cash Burn
- •Rich Valuation
INSM has strong gross margins and ample liquidity, but persistent operating losses, negative cash flow, and a demanding valuation make it a high-risk, capital-dependent story despite recent efficiency gains.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Weak rebound
Last month, INSM dropped about 24% from $144.48 to $109.14, with buyers defending $101-$103 but the failed rebound below $116-$118 and repeated lower highs leaving the short-term trend fragile and still bearish.
Brief oversold rebound to $117.99 after a sharp drop, but the move faded quickly
Sentiment & News
Key News Insights:
- •Institutional buying
- •Revenue miss
- •Pipeline progress
Insmed saw continued institutional interest and pipeline progress, but its Q1 revenue miss triggered a sharp stock drop despite solid product growth and reaffirmed guidance.
The news is mixed overall, with long-term growth catalysts intact but near-term sentiment pressured by the earnings miss and subsequent selloff
Similar Companies in Healthcare
Other companies in the same sector with AI ratings